Holen Sie sich die Stockscreener-App
1.90
2.06%
-0.04
Schlusskurs vom Vortag:
$1.94
Offen:
$1.935
24-Stunden-Volumen:
27,014
Relative Volume:
0.65
Marktkapitalisierung:
$92.33M
Einnahmen:
$18.11M
Nettoeinkommen (Verlust:
$-18.95M
KGV:
-4.3429
EPS:
-0.4375
Netto-Cashflow:
-
1W Leistung:
+0.00%
1M Leistung:
-0.26%
6M Leistung:
-3.06%
1J Leistung:
-38.41%
1-Tages-Spanne:
$1.90
$1.98
1-Wochen-Bereich:
$1.90
$1.98
52-Wochen-Spanne:
$1.325
$3.5807
Adagene Inc Adr Stock (ADAG) Company Profile
Vergleichen Sie ADAG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
1.90 | 92.33M | 18.11M | -18.95M | 0 | -0.4375 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.13 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
319.13 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.82 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.25 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-25 | Eingeleitet | China Renaissance | Buy |
| 2021-03-08 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Eingeleitet | Jefferies | Buy |
| 2021-03-08 | Eingeleitet | Morgan Stanley | Overweight |
Adagene Inc Adr Aktie (ADAG) Neueste Nachrichten
Adagene to present new ADG126 clinical data at ASCO-GI - MSN
Is McKesson (MCK) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Adagene Announces Participation At Leerink’s Global Healthcare Conference 2025 - Bernama
Adagene Inc. (NASDAQ:ADAG) Sees Significant Growth in Short Interest - Defense World
Adagene to Present at Jefferies Global Healthcare Conference 2025 - The Manila Times
Adagene Inc. to Participate in Jefferies Global Healthcare Conference 2025 with Fireside Chat and Investor Meetings - Nasdaq
Exclusive: Adagene Leadership Reveals Latest Antibody Therapeutic Strategy at Major Jefferies Conference - Stock Titan
Adagene (NASDAQ:ADAG) Trading Down 2.1% – Here’s Why - Defense World
Adagene Reports Promising ADG126 Study Results at ASCO - TipRanks
Adagene Announces Updated Data from Phase 1b/2 Study of - GlobeNewswire
New Clinical Data: Adagene's ADG126 Achieves Breakthrough 29% Response Rate in Hard-to-Treat Colorectal Cancer - Stock Titan
Adagene Inc. (NASDAQ:ADAG) Short Interest Update - Defense World
Adagene Appoints John Maraganore, Ph.D. as Executive Advisor - GlobeNewswire
Biotech Pioneer Behind $25B Alnylam Success Story Takes Strategic Role at Adagene's Cancer Drug Mission - Stock Titan
Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
Adagene Inc. Announces Poster Presentation on ADG126 at ASCO 2025 Conference - Nasdaq
Adagene Announces Upcoming Poster Presentation on Masked - GlobeNewswire
Adagene to Present at Stifel's 2025 Virtual Targeted Oncology Forum - The Manila Times
Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum - GlobeNewswire
Adagene Reveals New Oncology Strategy: CEO Set for Major Investor Presentation - Stock Titan
FY2025 Earnings Estimate for Adagene Issued By HC Wainwright - Defense World
Adagene (NASDAQ:ADAG) Earns “Buy” Rating from HC Wainwright - Defense World
Adagene stock hits 52-week low at $1.62 amid market challenges By Investing.com - Investing.com South Africa
Adagene stock hits 52-week low at $1.62 amid market challenges - Investing.com
Adagene (ADAG) to Release Quarterly Earnings on Thursday - Defense World
Adagene Reports 33% Overall Response Rate in Phase 2 Expansion of Muzastotug for MSS CRC, Highlights Financial Position and Future Milestones - Nasdaq
Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Adagene Reveals Breakthrough Cancer Trial Results in 2024 Financial Update - Stock Titan
Adagene Inc. (NASDAQ:ADAG) Short Interest Down 55.9% in February - Defense World
Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit - GlobeNewswire
Adagene Inc. to Present ADG126 SAFEbody® Data at 11th Annual Immuno-Oncology 360⁰ Summit in Boston - Nasdaq
Adagene's Revolutionary Cancer Treatment Targets CTLA-4: Key Presentation Coming to IO360 Summit - StockTitan
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024, Business Wires News - AsiaOne
Adagene to Present at Leerink’s Global Healthcare Conference 2025 - GlobeNewswire
Adagene to Present at Leerink's Global Healthcare Conference 2025 - The Manila Times
Can Adagene's CEO Reveal New Strategic Plans at Upcoming Leerink Conference? - StockTitan
Adagene Inc. to Initiate Phase 2 Trial of ADG126 for Colorectal Cancer with Enrollment Starting in April 2025 - Nasdaq
Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer - GlobeNewswire
Could This New Colorectal Cancer Trial Change Pre-Surgery Treatment? Adagene Tests ADG126 - StockTitan
Head to Head Analysis: Rafael (NYSE:RFL) versus Adagene (NASDAQ:ADAG) - Defense World
Short Interest in Adagene Inc. (NASDAQ:ADAG) Declines By 50.2% - MarketBeat
Head to Head Survey: Adagene (NASDAQ:ADAG) and Corvus Pharmaceuticals (NASDAQ:CRVS) - Defense World
Morgan Stanley Downgrades Adagene (NASDAQ:ADAG) to Equal Weight - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Sees Large Increase in Short Interest - MarketBeat
Adagene (NASDAQ:ADAG) Cut to “Equal Weight” at Morgan Stanley - Defense World
FY2024 Earnings Estimate for Adagene Issued By HC Wainwright - MarketBeat
Finanzdaten der Adagene Inc Adr-Aktie (ADAG)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.37%
0.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):